Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Alzheimer's disease --- Molecular aspects. --- Alzheimer disease --- Alzheimer's dementia --- Basal ganglia --- Presenile dementia --- Senile dementia --- Diseases --- Alzheimer Disease --- physiopathology.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Alzheimer's disease. --- Dementia. --- Aphrenia --- Aphronesia --- Athymia --- Dementias --- Brain --- Neurobehavioral disorders --- Psychoses --- Alzheimer disease --- Alzheimer's dementia --- Basal ganglia --- Presenile dementia --- Senile dementia --- Diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer’s disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. However, the fact that clinical trials of these drugs have not yet yielded satisfactory results has meant that for the time being patients continue to be treated only with symptomatic drugs. Currently, four such drugs are available: donepezil, galantamine, rivastigmine, and memantine. In this book, the four leading experts on each of these drugs explain their practical pharmacology with the aim of providing a sound basis for their use, which to date has been of questionable proficiency. In addition, an introductory chapter considers the basic theory of pharmacology for Alzheimer’s disease and the book closes with an overview of the ways in which symptomatic drugs are used for dementia.

Neurology. --- Pharmacy, Therapeutics, & Pharmacology --- Health & Biological Sciences --- Alzheimer's disease. --- Alzheimer's disease --- Chemotherapy. --- Treatment. --- Alzheimer disease --- Alzheimer's dementia --- Basal ganglia --- Presenile dementia --- Senile dementia --- Diseases --- Psychopharmacology. --- Pharmacotherapy. --- Medicine --- Nervous system --- Neuropsychiatry --- Behavioral pharmacology --- Drugs --- Chemotherapy --- Pharmacology --- Psychotropic drugs --- Psychotropic effects --- Neurology . --- Drug therapy --- Pharmacotherapy --- Therapeutics

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This compelling text provides an overview of the available technology for early detection and therapeutic management of vascular risk factors to Alzheimer’s before severe cognitive impairment symptoms appear. Chapters bring the reader from the trackless clinical research that has characterized Alzheimer’s progress for the last 20 years, to a nexus of new ideas and concepts that can change our outlook of this dementia. In-depth examinations of various hypotheses, preventive measures, current and prospective treatments are openly and clearly explored. The author discusses in depth his proposal of the vascular hypothesis of Alzheimer's disease which has become a mother-lode for basic and clinical studies and a key approach to the prevention of this dementia. Alzheimer’s Turning Point offers professionals, students and those looking to learn more about this disorder a fresh clinical perspective of this devastating disease. .

Medicine. --- Neurosciences. --- Neurology. --- Psychiatry. --- Medicine & Public Health. --- Alzheimer's disease. --- Alzheimer disease --- Alzheimer's dementia --- Basal ganglia --- Presenile dementia --- Senile dementia --- Diseases --- Neural sciences --- Neurological sciences --- Neuroscience --- Medical sciences --- Nervous system --- Medicine and psychology --- Mental health --- Psychology, Pathological --- Medicine --- Neuropsychiatry --- Neurology .

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Alzheimer's Disease: Lifecourse Perspectives on Risk Reduction summarizes the growing body of knowledge on the distribution and causes of Alzheimer's disease (AD) in human populations, providing the reader with knowledge on how we define the disease and what its risk and protective factors are in the context of a life-course approach. At the conclusion of the book, the reader will understand why Alzheimer's disease likely begins at conception, then progresses through early-life and adult risk factors that ultimately impact the balance between pathologic insults in the brain and the ability of the brain to modify disease symptoms. In contrast to edited volumes that may have little cohesion, this book focuses on an integrated life-course approach to the epidemiology of dementia, in particular, Alzheimer's disease.

Alzheimer's disease. --- Alzheimer Dementia --- Alzheimer Disease, Early Onset --- Alzheimer Disease, Late Onset --- Alzheimer Sclerosis --- Alzheimer Syndrome --- Alzheimer Type Senile Dementia --- Alzheimer's Disease --- Alzheimer's Disease, Focal Onset --- Alzheimer-Type Dementia (ATD) --- Dementia, Presenile --- Dementia, Primary Senile Degenerative --- Early Onset Alzheimer Disease --- Familial Alzheimer Disease (FAD) --- Focal Onset Alzheimer's Disease --- Late Onset Alzheimer Disease --- Primary Senile Degenerative Dementia --- Senile Dementia, Acute Confusional --- Acute Confusional Senile Dementia --- Dementia, Alzheimer Type --- Dementia, Senile --- Presenile Alzheimer Dementia --- Senile Dementia, Alzheimer Type --- Alzheimer Dementias --- Alzheimer Disease, Familial (FAD) --- Alzheimer Diseases, Familial (FAD) --- Alzheimer Type Dementia --- Alzheimer Type Dementia (ATD) --- Dementia, Alzheimer --- Dementia, Alzheimer-Type (ATD) --- Dementias, Alzheimer --- Familial Alzheimer Diseases (FAD) --- Presenile Dementia --- Sclerosis, Alzheimer --- Senile Dementia --- Alzheimer's Diseases --- Alzheimer Diseases --- Alzheimers Diseases --- Alzheimer Disease. --- Alzheimer's disease --- Alzheimer Disease --- Epidemiology. --- Prevention. --- epidemiology. --- Alzheimer disease --- Alzheimer's dementia --- Basal ganglia --- Presenile dementia --- Senile dementia --- Diseases